<?xml version="1.0" encoding="UTF-8"?>
<p id="p0445">It had been suggested that the use of ACE-I and ARB drugs for cardiovascular indications could lead to an up-regulation of ACE2 receptors, and hence the development of more severe COVID-19 
 <xref rid="b0840" ref-type="bibr">[168]</xref>. However, the European Heart Association as well as three major American cardiology bodies, including the American Heart Association, the American College of Cardiology, and the Heart Failure Society of America, have all emphasized that patients who have been taking ACE-I or ARB drugs should continue their treatment.
</p>
